ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of ADCT-602’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for ADCT-602 is expected to reach an annual total of $53 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

ADCT-602 Overview

ADCT-602 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia. The therapeutic candidate is administered through intravenous route. It is an antibody drug conjugate composed of the humanized anti-human CD22 monoclonal antibody epratuzumab (hLL2) conjugated to pyrrolobenzodiazepine PBD dimer toxin. The drug candidate is developed based on pyrrolobenzodiazepine (PBD) technology. This technology enables cytotoxic agents to target antibodies using biodegradable linkers. It was also under development for non-Hodgkin lymphoma such as diffuse large B-cell lymphoma.

ADC Therapeutics Overview

ADC Therapeutics is a commercial-stage biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It develops drugs by using PBD dimer technology. The company’s pipeline products include loncastuximab tesirine-lpyl, an ADC composed of a humanized monoclonal antibody that binds to human CD19 and treats B-cell lymphoma; ADCT-602 is a monoclonal antibody that binds to CD22 targets acute lymphoblastic leukemia; ADCT-601 (mipasetamab uzoptirine) is a humanized monoclonal antibody that binds to human AXL treats various solid tumors; and Claudin-6, NaPi2b and PSMA. The company operates through its subsidiaries in the US, the UK and the Netherlands. ADC Therapeutics is headquartered in Lausanne, Switzerland.
The company reported revenues of (US Dollars) US$69.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 66.9% over FY2022. The operating loss of the company was US$166 million in FY2023, compared to an operating loss of US$165.5 million in FY2022. The net loss of the company was US$240.1 million in FY2023, compared to a net loss of US$157.1 million in FY2022.

For a complete picture of ADCT-602’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.